Express Pharma

NRx Pharmaceuticals announces positive safety report for Zyesami in NIH-sponsored ACTIV-3 study in COVID-19 patients 

ACTIV-3 Critical Care is evaluating Zyesami and Remdesivir in critical COVID-19 patients as monotherapy, and in combination against placebo